Fecal Microbiota Transplantation for Liver Failure

Launched by NINGBO MEDICAL CENTER LIHUILI HOSPITAL · Dec 9, 2021

Keywords

ClinConnect Summary

This clinical trial is exploring a treatment called fecal microbiota transplantation (FMT) for people with liver failure. FMT involves taking healthy bacteria from a donor's stool and placing it into the intestines of a patient. The goal of the study is to see if this treatment is safe, if there are any side effects, and whether it can help improve the health of patients with liver failure. Researchers will also look at how FMT affects the balance of bacteria in the gut and the connection between the gut and the liver, which is known as the "gut-liver axis."

To join the trial, participants must be between 18 and 65 years old and have been diagnosed with liver failure that includes symptoms like severe jaundice (yellowing of the skin and eyes) and bleeding problems. However, individuals with certain serious health conditions, such as severe heart or lung diseases, cancer, or those taking specific medications, may not be eligible. If someone joins the study, they can expect to receive careful monitoring and support throughout the process, helping researchers understand the potential benefits of this innovative treatment for liver failure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients willing to sign informed consent
• • Patients aged 18-65
• • According to the diagnosis standard of liver failure in the guide for diagnosis and treatment of liver failure (2018 Edition), the eligible patients are included, that is, on the basis of chronic liver disease, the syndrome with acute jaundice deepening and coagulation dysfunction as the manifestation of liver failure caused by various inducements can be combined with complications such as Hepatoencephalopathy, ascites, electrolyte disorder, infection, hepatorenal syndrome, hepatopulmonary syndrome, etc And extrahepatic organ failure. The patient's jaundice deepened rapidly, the serum TBIL ≥ 10 × ULN or the daily rise ≥ 17.1 μ mol / L; there was bleeding, PTA ≤ 40% (or INR ≥ 1.5)
• Exclusion Criteria:
• • Patients with severe heart failure, COPD, cerebrovascular accident, nephrotic syndrome, etc;
• • Patients with gastrointestinal bleeding, pulmonary infection, septicemia, etc
• • Patients with liver cancer, lung cancer, lymphoma and other malignant tumors
• • Patients taking anticoagulants, mental diseases and immune diseases for a long time
• • Pregnant or lactating women.